Browse the evidence

GLP-1 analogs may interact with estrogens.

Consideration of estrogen interactions may be important in treatment plans involving GLP-1 analogs.

69,213,936 prescriptions for obesity medications (OMDs) were dispensed in the US from July 2017 to February 2024, with a mean annual growth rate of 5.3%.

Healthcare providers should be aware of the increasing trend in OMD prescriptions.

Pre-operative semaglutide use within 10 days of elective surgical procedures was independently associated with increased risk of residual gastric content on pre-operative gastric ultrasound assessment.

Practitioners should consider the timing of semaglutide administration in relation to elective surgeries to mitigate the risk of increased residual gastric content.

Semaglutide treatment resulted in lower rates of non-CV death, primarily due to fewer infectious deaths (HR: 0.71; 95% CI: 0.51-0.98).

Reducing infectious deaths may be a significant benefit of semaglutide in this population.

Among participants who developed COVID-19, those treated with semaglutide had fewer COVID-19-related serious adverse events and deaths (HR: 0.66; 95% CI: 0.44-0.96).

Semaglutide may provide protective benefits against severe outcomes from COVID-19 in this population.

Active GLP-1 RA prescription was associated with a significant reduction in postoperative hematoma (RR: 0.440; P = 0.023).

Consideration of GLP-1 RA may help in minimizing hematoma risks in surgical patients.

Short-acting GLP-1 receptor agonists are associated with an increased risk of erosive reflux disease (ERD) with a hazard ratio (HR) of 1.215.

Clinicians should be cautious when prescribing short-acting GLP-1 RAs to patients with type 2 diabetes due to the increased risk of ERD.

Short-acting GLP-1 receptor agonists are associated with an increased risk of oesophageal stricture with a hazard ratio (HR) of 1.284.

Healthcare providers should monitor for signs of oesophageal stricture in patients using short-acting GLP-1 RAs.

Short-acting GLP-1 receptor agonists are associated with an increased risk of Barrett's esophagus with dysplasia with a hazard ratio (HR) of 1.505.

Clinicians should be aware of the potential risk of Barrett's esophagus with dysplasia in patients prescribed short-acting GLP-1 RAs.

Perioperative semaglutide use is associated with increased residual gastric content (RGC) in patients undergoing elective esophagogastroduodenoscopy.

Clinicians should consider the timing of semaglutide administration in relation to elective procedures to mitigate RGC risk.

The contribution of the GIP receptor-activating component of tirzepatide to its effects is uncertain.

Further research is needed to clarify how GIP receptor activation contributes to the effects of tirzepatide.

GLP-1 RAs showed long-term protective effects on renal outcomes and adverse events.

GLP-1 RAs may provide long-term benefits for kidney health in obese individuals without T2D.

In patients with cardiometabolic HFpEF, tirzepatide showed a 58% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Tirzepatide may also be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

GLP-1-RAs are known to delay gastric emptying.

Understanding the effect of GLP-1-RAs on gastric emptying is crucial for perioperative management.

GIP accounts for 60% to 80% of the postprandial insulin response.

Understanding GIP's role can help in managing postprandial insulin levels.

GIP is overexpressed in obese individuals, which may exacerbate insulin resistance.

Addressing GIP levels may be important in treating obesity-related insulin resistance.

The safety profile of tirzepatide was broadly similar across BMI and age subgroups, but drug discontinuation due to adverse events was higher in participants aged ≥ 65 years.

While generally safe, practitioners should monitor older patients closely when prescribing tirzepatide.

Ghrelin is an orexigenic hormone, while GLP-1, GIP, CCK, PYY, and OXM are anorexigenic hormones.

Understanding the roles of these hormones can help in developing targeted interventions for appetite regulation.

Antidiabetic medications can reduce the risk and improve outcomes of cardiovascular diseases.

Consider the cardiovascular benefits when prescribing antidiabetic medications.

New approaches in GLP-1RAs development include multi-agonists and combination therapies.

Practitioners should explore the potential benefits of multi-agonist and combination therapy strategies in GLP-1RA treatments.

Novel GLP-1-based therapeutics are rapidly advancing and may reshape the future landscape of obesity and type 2 diabetes treatment.

Practitioners should consider the potential of these novel agents in treating obesity and type 2 diabetes.

Triple agonists such as retatrutide target GIP, GLP-1, and glucagon receptors to amplify metabolic effects.

Consider the potential of triple agonists in enhancing metabolic outcomes for patients.

Meta-regression suggested no significant correlation between BP reduction and baseline characteristics such as age, gender, HbA1c, weight, BMI, and percentage of patients with hypertension.

GLP-1 receptor agonists may be effective for BP management regardless of certain baseline characteristics.

Tirzepatide, a GLP-1/GIP receptor co-agonist, was approved by the FDA for the treatment of T2DM and provides superior HbA1c reductions.

Healthcare providers can utilize tirzepatide as a more effective treatment option for T2DM.